In particular, in clinical trials and post-marketing reports, pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia were identified in patients who received monoclonal antibodies including TNF blockers (28). This evidence concerns the gene TNF and aplastic anemia.